Genmab A/S Stock Nasdaq
Stocks
GMAB
US3723032062
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Nasdaq
07:00:00 29/10/26 am AEDT
|
Pre-market 12:14:51 am | |||
| 57.29 USD | +28.25% |
|
56.53 | -1.33% |
| 08:46pm | Goldman Sachs raises its price target for Genmab to 4,450 Danish kroner (2,400), reiterates buy | FW |
| 07:25pm | Genmab: Positive developments priced in; time to take profits |  |
| Market Cap | 231B 34.47B 30.93B 28.6B 25.9B 48.38B 3,283B 48.97B 342B 136B 1,718B 129B 127B 5,454B | P/E 2026 * |
47.2x | P/E 2027 * | 32.2x |
|---|---|---|---|---|---|
| Enterprise Value | 251B 37.43B 33.58B 31.05B 28.12B 52.53B 3,565B 53.16B 371B 148B 1,865B 140B 137B 5,922B | EV / Sales 2026 * |
8.36x | EV / Sales 2027 * | 6.76x |
| Free-Float |
94.3% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| GMAB | Delayed | |
CBOE
| GMAB | Real-time | |
|
Tradegate
| GE91 | Real-time | |
|
Boerse Muenchen
| GE91 | Real-time | |
|
Deutsche Boerse AG
| GE91 | Delayed | |
|
Börse Stuttgart
| GE91 | Delayed |
Last Transcript: Genmab A/S
| 1 day | -1.97% | ||
| 1 week | +44.78% | ||
| Current month | +60.59% | ||
| 1 month | +62.02% | ||
| 3 months | +97.55% | ||
| 6 months | +113.85% | ||
| Current year | +86.01% |
| 1 week | 39.64 |  | 59.97 |
| 1 month | 33.72 | | 59.97 |
| Current year | 23.62 | | 59.97 |
| 1 year | 23.62 | | 59.97 |
| 3 years | 17.24 | | 59.97 |
| 5 years | 17.24 | | 59.97 |
| 10 years | 12.1 | | 59.97 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 01/06/2010 | |
Anthony Pagano
DFI | Director of Finance/CFO | 48 | 01/03/2020 |
Rayne Waller
CTO | Chief Tech/Sci/R&D Officer | - | 16/08/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 75 | 01/11/2003 | |
| Director/Board Member | 58 | 01/01/2015 | |
| Director/Board Member | 75 | 01/01/2015 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +28.25% | +44.78% | - | - | 34.47B | |
| +0.65% | -3.36% | +36.98% | +60.50% | 64.14B | |
| +1.46% | +3.17% | +12.78% | +84.77% | 55.53B | |
| +1.81% | +1.75% | +13.01% | +105.20% | 53.03B | |
| +2.76% | +0.87% | +27.92% | +55.07% | 45.99B | |
| +2.00% | -3.39% | +17.83% | +119.04% | 42.45B | |
| +1.34% | -2.86% | +224.43% | +914.08% | 40.45B | |
| +0.64% | -3.95% | +11.15% | +45.57% | 32.25B | |
| -2.55% | +42.88% | +103.98% | +90.46% | 34.47B | |
| -2.72% | -0.44% | +23.18% | -10.77% | 24.23B | |
| Average | +0.03% | +4.08% | +52.36% | +162.66% | 43.62B | |
| Weighted average by Cap. | +0.36% | +3.49% | +49.41% | +160.63% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 29.99B 4.47B 4.01B 3.71B 3.36B 6.28B 426B 6.35B 44.36B 17.67B 223B 16.79B 16.43B 708B | 35.92B 5.36B 4.81B 4.44B 4.03B 7.52B 510B 7.61B 53.14B 21.17B 267B 20.11B 19.68B 848B |
| Net income | 5.13B 766M 687M 635M 575M 1.07B 72.91B 1.09B 7.59B 3.02B 38.15B 2.87B 2.81B 121B | 7.55B 1.13B 1.01B 934M 846M 1.58B 107B 1.6B 11.17B 4.45B 56.13B 4.23B 4.14B 178B |
| Net Debt | 19.8B 2.95B 2.65B 2.45B 2.22B 4.15B 281B 4.2B 29.29B 11.67B 147B 11.08B 10.85B 467B | 11.95B 1.78B 1.6B 1.48B 1.34B 2.5B 170B 2.53B 17.67B 7.04B 88.81B 6.69B 6.55B 282B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 28/10/26 | USD 57.29 | +28.25% | 29,283,870 |
| 27/10/26 | USD 44.67 | -0.03% | 4,929,100 |
| 26/10/26 | USD 44.69 | +2.04% | 7,473,717 |
| 23/10/26 | USD 43.79 | +9.47% | 13,000,825 |
| 22/10/26 | USD 40.00 | +1.09% | 4,685,776 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GMAB Stock
- GMAB Stock
Select your edition
All financial news and data tailored to specific country editions
